Effects of Newly Developed Anticancer Drugs Against GI101Aluc Mammary Tumor Implanted in Athymic Nude Mice

Effects of Newly Developed Anticancer Drugs Against GI101Aluc Mammary Tumor Implanted in Athymic Nude Mice

The purpose of this research is screening anti-cancer drugs using tumor bearing animals. To achieve this, we used a mammary tumor cell line GI-101A that was developed from a metastatic breast tumor xenograft. The GI-101A cell line had been previously transfected to express the luciferase gene (GI-101Aluc). Luciferase expression in the tumor cells enables the imaging of tumors in a molecular imager rather than performing surgery. For drug screening analysis, twenty-four athymic nude mice were implanted subcutaneously with GI-101Aluc cells. The animals were rested for 3 weeks after implantation for establishing tumor growth. During this period their weight and tumor volume were monitored weekly. When the primary tumors reached a volume of 100mm3, the mice were treated orally and intraperitoneally with anti-cancer agents code named MH51 and JFD. Sodium Phenylacetate [NaPA] and Cisplatin were used as their respective positive controls in our experiments. JFD compound was injected intraperitoneally and compound MH51 was given orally ad libitum. Their cytotoxic and cytostatic effects were monitored using real time in vivo molecular imaging techniques. Our current results include successful implantation of luciferase expressing cancer cells and generation of palpable primary tumors in nude mice. After 3 weeks of treatment, regression of the tumors was observed with Cisplatin, and JFD drugs while compound MH51 did not show any significant changes. The drug treatment was continued for another 3 weeks. (This research was supported by generous donations from the Royal Dames, Inc.)